Trial
NCT04338269
A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Hoffmann-La Roche
Collaborators
Exelixis; Chugai Pharmaceutical
Condition
Carcinoma, Renal Cell
Intervention
Atezolizumab
Why stopped
As the study did not meet it's primary endpoint a decision was made to terminate the study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-03-19